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Abstract: Introduction: Neuroleptic cardiomyopathy (NCMP) belongs to secondary specific metabolic dilated 
cardiomyopathies. It is caused by side cardiotoxic effect of antipsychotic drugs. Many aspects of epidemiology, 
pathogenesis, morphology, clinical picture and diagnostics of NCMP still remain insufficiently explored. 
Results: NCMP passes through 3 stages in its development: 1) a latent one, 2) a full-scale one, and 3) a terminal one. 
Each stage has clinical features, electrocardiograph signs and certain morphology. 
Lethal termination in a latent and in a full-scale stage either takes place because of intercurrent diseases or it is a 
sudden cardiac death of arrythmogenic genesis. In the terminal stage, the direct cause of death is, as a rule, a 
progressive congestive chronic cardiac failure. 
On the macroscopic level, NCMP is characterized by a moderate cardiomegaly; by a noticeable dilatation of heart 
ventricles; by absence of evident coronary atherosclerosis. 
On the microscopic level, all structural components of myocardium (microvasculature, intercellular matrix, 
cardiomyocytes) are deeply damaged. These pathologic changes are a physical basis of a contractile myocardial 
dysfunction. 
Conclusion: On the basis of the summarizing of the data, which were received in a series of studies, we singled out and 
proved clinical and morphological criteria of diagnostics of NCMP.  
Taking the described clinical and morphologic peculiarities of NCMP into account, it is advisable and quite logic to single-
out this pathology into an independent nosologic unit. 
Keywords: Neuroleptics, Cardiotoxicity, Clinical picture, Diagnostics, Morphology, Neuroleptic cardiomyopathy, 
Nosological independence. 
INTRODUCTION 
Neuroleptic cardiomyopathy (NCMP) is one of 
serious complications of psychotropic therapy, this 
complication is caused by a side cardiotoxic effect of 
antipsychotic drugs [1-4]. 
This disease belongs to secondary specific 
metabolic dilated cardiomyopathies [5, 6, 7] and is 
characterized by a diffuse myocardial involvement, by a 
drastic reduction of its contractile function and, as 
consequence, by a progressive congestive chronic 
cardiac failure (CCF) [2, 5, 6, 8-10]. 
Many aspects of epidemiology, pathogenesis, 
morphology, clinical picture and diagnostics of NCMP 
still remain insufficiently explored. 
The goal of the real review is the short 
generalization of the results of the own researches of 
this problem.  
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RESULTS 
According to our autopsy findings, among dead 
patients who had schizophrenia and whose obligatory 
therapy component had been the intake of 
antipsychotic drugs, the number of persons having 
NCMP is considerable and statistically significantly 
higher (11.4%) than in the total autopsy material of the 
psychiatric prosectorium on the whole (2.0%) [8]. 
NCMP passes through 3 stages in its development: 
1) a latent one, clinically fully compensated one, 2) a 
full-scale one, when cardiac disorders are clearly 
detected, but without evident signs of CCF, and 3) a 
terminal one, when the clinical picture of CCF comes to 
the foreground [9, 11-13]. 
Lethal termination in a latent and in a full-scale 
stage either takes place because of intercurrent 
diseases or it is a sudden cardiac death (SCD) of 
arrythmogenic genesis [5, 11, 13]. The latter, according 
to our data, is observed in 44.2% patients who died of 
NCMP [14, 15]. In the terminal stage, the direct cause 
of death is, as a rule, a progressive CCF [5, 11, 13]. 
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The disease develops slowly and at first hardly 
noticeably. In the latent stage it does not practically 
manifest itself. 
In this period the patients' complaints are indefinite 
or fully absent. Patients most often complain about 
fatigability and dyspnea on significant exertion. In this 
regard one has to take certain difficulties of detection of 
mentally sick patients' complaints into account, on the 
one hand because of their abnormal behavior and 
absence of due critical approach to their own state, and 
on the other hand because of the quite often certain 
drug-induced loadedness. 
Physical findings in the latent stage of NCMP are 
not numerous and not specific too. As a rule, 
tachycardia is observed, which is a practically constant 
phenomenon accompanying intake of neuroleptics [1]. 
Reduction of heart tones is determined by auscultation. 
Heart borders are usually little changed. As for arterial 
pressure (AP), hypotonia and normotonia considerably 
prevail; an insignificant arterial hypertension (AH) is 
observed only in approximately one third of cases [5, 
11]. 
In this period the following pathologic signs are 
most often present on an electrocardiogram (ECG): 1) 
diffuse muscular changes; 2) various types of 
asequence, in particular, left bundle-branch block; 3) 
axis deviation to the left; 4) overload of venous heart; 
5) left ventricular hypertrophy [5, 6, 8-10, 16]. 
In the full-scale stage the clinical picture of NCMP 
manifests itself clearly enough, but signs of a terminal 
CCF are absent or little noticeable. Patients' complaints 
are more definite: weakness, fatigability, heartbeats, 
dyspnea on significant exertion, sometimes intermittent 
pains in the heart area. Dullness of heart tones, some 
expansion of heart borders, tachycardia, intermittent 
tachypnea are physically detected. In this period a 
stably normal AP and a labile one with a tendency to a 
moderate AH are equally often observed [5, 11]. 
The terminal stage of NCMP course is 
characterized by addition of known manifestations of 
an increasing congestive CCF to the already named 
symptoms, among these manifestations are: dyspnea 
at rest or on minor exertion, orthopnea, enlargement of 
liver, peripheral and cavitary edemas, sometimes 
anasarca etc. By percussion one detects that heart 
borders are moderately - or less often, more 
significantly - expanded, what is confirmed by an X-ray 
examination. Heart tones are dull, tachycardia is almost 
always present, and arrhythmia is often present. A 
moderate AH is observed in a little more than one-
fourth of patients, the AP of 13.6% other patients 
constantly exceeds 150/100 mm Hg [5, 11]. 
On an ECG, in the full-scale and terminal stages of 
NCMP the following phenomena are the most alarming 
ones: 1) asequence; 2) prolongation of the QT interval 
recalculated on Bazett's formula - the corrected QT 
interval (QTс); 3) overload of venous heart [5, 6, 8-10, 
16]. A special attention must be paid to the monitoring 
of parameters of the QTс interval as a highly 
informative factor in the case of cardiac 
decompensation [17]. 
On the macroscopic level (organ one), NCMP is 
characterized by a moderate cardiomegaly; by a 
noticeable almost uniform dilatation of heart ventricles 
with a some predominance of dilatation of the left one; 
by absence of evident coronary atherosclerosis, 
especially in persons older than 45 years. 
When microscopic examination of myocardium 
(tissular and cellular levels) is conducted, an evident 
myofibrosis and small-focal (substitutive) 
cardiosclerosis, a chronic interstitial edema, at first 
hypertrophic and then dystrophic-degenerative and 
atrophic changes of cardiomyocytes are detected. 
At early stages microcirculation violations are 
detected. Damages of an intercellular matrix (an 
interstitial edema and a myofibrosis) develop then. 
Dystrophic-degenerative and atrophic changes of 
cardiomyocytes come to the foreground in a terminal 
stage.  
DISCUSSION 
The high frequency of NСMP in patients with 
schizophrenia is evidence that just the wide use of 
neuroleptics in medical practice is the cause of 
development of the given cardiac pathology in these 
patients. 
It is seen from our researches clinical diagnostics of 
NCMP is difficult, because its symptomatology has no 
specific traits [18]. 
On the basis of the summarizing of the data, which 
were received in a series of studies [2, 6, 8, 10], we 
singled out and proved clinical criteria of diagnostics of 
NCMP [5, 18, 19]. The diagnostic scheme is imagined 
in the approximately following way. 
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Large Criteria (absolute ones) 
• Treatment with neuroleptics; 
• Absence of another cardiac pathology. 
Minor Criteria (relative ones) 
• Cardiac complaints (even minimal ones); 
• Enlargement of heart size (detection by 
percussion and by an X-ray examination); 
• Physical findings (tachycardia, arrhythmia, 
dullness of heart tones); 
• Changes of an ECG, especially an increase of 
the QTс interval, rhythm disturbance and 
asequence; 
• Presence of a congestive CCF when other 
causes of its development are absent; 
• Patient’s SCD (important for postmortal 
diagnostics). 
It is important to emphasize that each of the above-
named signs - if taken separately, without connection 
with others - is not specific for NCMP. But taken 
together, these criteria can become a reliable basis for 
clinical verification of the disease. The main factor, 
which makes us think of NCMP, is a long intake of 
antipsychotic drugs. 
There is reason to believe that the both large signs 
and at least two minor ones must be present for 
diagnostics of NCMP. But further research and 
accumulation of practical experience are nevertheless 
required in this direction. In particular, the 2nd large 
criterion can become ineffective after conduction of 
research on comorbidity of NCMP and other heart 
diseases, in particular, ischemic cardiomyopathy, 
especially in persons older than 45 years. 
But already in this stage, the proposed criteria of 
NCMP diagnostics and approximate diagnostic scheme 
can, from our point of view, become useful for early 
detection of this serious complication of neuroleptic 
therapy for the purpose of its timely corrective 
treatment. 
Postmortal diagnostics of NCMP cause certain 
difficulties, too. They are mainly connected with 
insufficient development of morphologic criteria 
allowing a pathologist to diagnose NCMP [20]. 
Results of own NCMP morphology study, what we 
conducted on various levels of research, elucidate the 
pathologicoanatomic picture of this pathology full 
enough. 
In the course of NCMP morphogenesis all structural 
components of myocardium (microvasculature, 
intercellular matrix, cardiomyocytes) are deeply 
damaged, what sharply reduces its contractile 
reserves. And detected pathologic changes of cardiac 
muscle microstructure reflect deep tissular changes of 
dystrophic-degenerative, sclerotic and - to a lesser 
degree - compensatory-adaptive character, which 
develop in the myocardium in the process of NCMP 
morphogenesis. All above-named pathologic changes 
are objective, reliable morphologic signs and a physical 
basis of a myocardial dysfunction [21, 22], which 
ultimately leads to advance of a fatal CCF. 
Each of these signs in it self - if taken separately - is 
not specific for NCMP. But taken together, the above-
named morphologic changes form a sufficiently reliable 
basis for pathologicoanatomic diagnostics of this 
disease [12, 19, 20]. 
Thus, NСMP possesses all signs of the concept 
"illness" that is has own epidemiology, etiology, 
pathogenesis, clinic and morphology. 
CONCLUSION 
Taking the described clinical and morphologic 
peculiarities of NCMP into account, it is advisable and 
quite logic to single-out this pathology into an 
independent nosologic unit. According to the ICD-10 it 
can be placed under the code I42.7 “Cardiomyopathy, 
caused by effect of drugs and other external factors”, 
with an additional code which reflects the external 
cause of the disease (class of antipsychotic drugs) – 
Y49.3-Y49.5 [5, 16]. 
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